This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Investigating the Phase 3 STRIDE-3 Clinical trial data on V116 presented at World Vaccine Congress West Coast
Ticker(s): MRKWho's the expert?
- Very Familiar with Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine Candidate
- Treats 10-15 patients per month with pneumococcal disease
- Runs private practice in New York
Interview Goalto discuss the current standard of care and the potential of V116, an investigational 21-valent pneumococcal conjugate vaccine being developed by Merck.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
